Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an announcement.
Radiopharm Theranostics Limited announced a proposed issue of 30,969,360 ordinary fully paid securities, with the issuance date set for June 13, 2025. This move is part of a strategic placement to potentially enhance the company’s capital structure, which could strengthen its market position and provide additional resources for its ongoing projects in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is committed to advancing innovative solutions in the field of nuclear medicine, aiming to enhance patient outcomes through targeted radiotherapy and imaging technologies.
Average Trading Volume: 4,436,932
Technical Sentiment Signal: Sell
Current Market Cap: A$58.35M
See more data about RAD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue